Royalty Pharma plc
Royalty Pharma plc
Your view on RPRX
Overview
What the company does, where it operates, and who runs it.
About Royalty Pharma plc
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Pablo Gerardo Legorreta
- Headquarters
- 110 East 59th Street, New York City, NY, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Pablo Gerardo Legorreta
- Headquarters
- 110 East 59th Street, New York City, NY, US
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies.
In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Royalty Pharma plc from FRC's valuation model, read against the market price. RPRX last traded at $70.01, 41.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Royalty Pharma plc. Starting points for Royalty Pharma plc: P/E 41.4, EPS $1.51, beta 0.41 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Royalty Pharma plc. Royalty Pharma plc paid $0.93 per share over the last year — a 1.3% yield at the current $70.01 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Royalty Pharma plc. Trailing twelve-month EPS for Royalty Pharma plc stands at $1.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$66.00
Median
$66.50
High
$67.00
Average target · 1 new target in the last 3 months, average $67.00
Analyst Ratings
- Strong Buy0
- Buy11
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.57 | $1.13 | $5.39 | $5.91 |
| Low estimate | $1.53 | $1.11 | $5.34 | $5.73 |
| High estimate | $1.62 | $1.14 | $5.43 | $6.04 |
| No. of analysts | 5 | 1 | 4 | 4 |
| Year-ago EPS | $0.50 | $0.53 | $1.80 | — |
| Growth | +213.3% | +112.3% | +199.6% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $960.74M | $777.10M | $3.54B | $3.86B |
| Low estimate | $942.91M | $768.03M | $3.52B | $3.83B |
| High estimate | $978.56M | $784.82M | $3.56B | $3.88B |
| No. of analysts | 2 | 1 | 4 | 3 |
| Year-ago revenue | $621.99M | $630.58M | $2.38B | — |
| Growth | +54.5% | +23.2% | +48.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Royalty Pharma plc. Royalty Pharma plc has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Royalty Pharma plc valued side by side against its closest peers. Royalty Pharma plc is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Royalty Pharma plc, and how their positions are changing. At a $31.17B market value, institutional positions materially move Royalty Pharma plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Royalty Pharma plc executives and directors. Shares of Royalty Pharma plc have traded between $24.05 and $41.24 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Royalty Pharma plc. Coverage tracks Royalty Pharma plc within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Royalty Pharma plc.